Fig. 4From: First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysisOne-way sensitivity analysis in patients with non-epithelioid histology. N Patients with non-epithelioid histology, NI Nivolumab plus ipilimumab, C Pemetrexed plus cisplatin/carboplatin, PD Progressive disease, PFS Progression-free survival, WTP Willingness to pay, EV Average value, QALY Quality-adjusted life yearBack to article page